Gemcitabine and cisplatin treatment over a 3-week versus a 4-week dosing schedule: a randomized trial conducted in Chinese patients with nonsmall cell lung cancer / 中华医学杂志(英文版)
Chinese Medical Journal
;
(24): 892-897, 2008.
Artigo
em Inglês
| WPRIM
| ID: wpr-258570
ABSTRACT
<p><b>BACKGROUND</b>Gemcitabine plus cisplatin is a standard treatment for stages IIIB and IV nonsmall cell lung cancer (NSCLC). This randomized phase II study evaluated a 3-week versus a 4-week schedule of gemcitabine-cisplatin as first line treatment for Chinese patients with advanced NSCLC.</p><p><b>METHODS</b>Patients were randomized to receive cisplatin 75 mg/m(2) on day 1 plus either gemcitabine 1250 mg/m(2) on days 1 and 8 of a 21-day cycle (3-week group) or gemcitabine 1000 mg/m(2) on days 1, 8 and 15 of a 28-day cycle (4-week group).</p><p><b>RESULTS</b>One hundred patients were enrolled in this study. The response rate was 24% (12/51 patients) in the 3-week group and 27% (13/49 patients) in the 4-week group. There were no statistically significant differences between the two treatment groups in survival (hazard ratio 1.19; 95% CI 0.68 - 2.09) with a median survival of 12.1 months and 13.8 months in the 3-week group and the 4-week group respectively. The rate of grade 3/4 toxicity in the 3-week group was 55% compared with 86% in the 4-week group (P = 0.001). The difference in the incidence of grade 3/4 haematological toxicities did not reach statistical significance (3-week 37%, 4-week 57%), however grade 3/4 drug related neutropenia (3-week 27%, 4-week 51%) and thrombocytopenia (3-week 8%, 4-week 31%) were significantly lower in the 3-week group. Grade 3/4 nonhaematological toxicities were less in the 3-week group (33% cf 63%; P = 0.005).</p><p><b>CONCLUSIONS</b>The differences in the efficacy endpoints were all in favour of the 4-week schedule of gemcitabine plus cisplatin, however these differences did not reach statistical significance. Fewer grade 3/4 toxicities were observed in the 3-week group compared with the 4-week group.</p>
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Esquema de Medicação
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
China
/
Cisplatino
/
Resultado do Tratamento
/
Carcinoma Pulmonar de Células não Pequenas
/
Usos Terapêuticos
/
Povo Asiático
/
Desoxicitidina
/
Tratamento Farmacológico
Tipo de estudo:
Ensaio Clínico Controlado
Limite:
Adulto
/
Idoso
/
Feminino
/
Humanos
/
Masculino
País/Região como assunto:
Ásia
Idioma:
Inglês
Revista:
Chinese Medical Journal
Ano de publicação:
2008
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS